Miasuma 
EQPT Stock: Is EquipmentShare’s $500M Buyback Enough to Offset Its Debt Risk? EquipmentShare.com Inc. (NASDAQ: EQPT) surged after raising its 2026 financial outlook and announcing a new $500 million share repurchase program. The announcement gave investors a clear reason to revisit the stock after a difficult post-IPO trading period. But the real question is not … Read more
WDFC Stock Analysis: WD-40 Surges on 24% Revenue Growth, Raised Guidance and $100M Buyback WD-40 Company (NASDAQ: WDFC) surged after reporting much stronger-than-expected fiscal third-quarter 2026 results, raising its full-year outlook, and announcing a new $100 million share repurchase program. At the latest market check, WDFC was trading around $272.42, with an intraday range of … Read more
LASR Stock Analysis: nLIGHT Surges as HADES Directed Energy Lasers and Defense Demand Drive Revaluation nLIGHT, Inc. (NASDAQ: LASR) surged as investors focused on the company’s role in directed energy weapons, counter-drone defense, high-energy laser systems, and stronger aerospace and defense revenue. At the latest market check, LASR was trading around $71.00, up more than … Read more
BABA Stock Analysis: Alibaba Surges as AI Cloud Growth, Qwen and China Tech Rally Drive Revaluation Alibaba Group Holding Ltd. (NYSE: BABA, HK: 9988) jumped sharply as investors rotated back into China technology stocks and reassessed Alibaba’s role in AI, cloud infrastructure, and consumer commerce. At the time of writing, BABA ADR was trading around … Read more
PENG Stock: Penguin Solutions Surges After Q3 Earnings, Integrated Memory Growth and AI Factory Demand Penguin Solutions, Inc. (NASDAQ: PENG) surged after reporting record fiscal third-quarter 2026 results and raising its full-year outlook. The rally was not just another AI headline move. This was an earnings-driven revaluation based on stronger revenue, higher EPS guidance, surging … Read more
AGIO Stock Analysis: Mitapivat FDA Priority Review, November 2026 PDUFA Date and the Sickle Cell Disease Opportunity Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) surged after the U.S. Food and Drug Administration granted Priority Review to the company’s supplemental New Drug Application for mitapivat in sickle cell disease. The FDA assigned a PDUFA goal date of November … Read more
DOCN Stock Analysis: DigitalOcean’s AI-Native Cloud, 221% AI ARR Growth and the Intraday Reversal Risk DigitalOcean Holdings, Inc. (NYSE: DOCN) is no longer being viewed only as a developer-first cloud platform for startups and small businesses. After launching its AI-Native Cloud and reporting rapid growth in AI customer revenue, the market is starting to reprice … Read more
SHAZ Stock Analysis: SharonAI’s NVIDIA AI Factory Deal, 40,000 GB300 GPUs and the Risks Investors Should Know SharonAI Holdings, Inc. (NASDAQ: SHAZ) has quickly become one of the most talked-about AI infrastructure stocks after announcing a six-year strategic compute collaboration with NVIDIA. The agreement is designed to enable 72 megawatts of new data center capacity … Read more
SEER Stock Analysis: Why Seer Is Surging After the $2.45 Buyout Proposal Seer, Inc. (NASDAQ: SEER) jumped sharply after the company received an unsolicited, non-binding acquisition proposal from its Chair and CEO, Omid Farokhzad, M.D. The proposal would acquire all outstanding shares of Seer’s Class A common stock for $2.45 per share in cash, plus … Read more
WULF Stock Analysis: Why TeraWulf Is Surging on Its $19 Billion Anthropic AI Data Center Deal TeraWulf Inc. (NASDAQ: WULF) has become one of the most closely watched AI infrastructure stocks after announcing a major 20-year lease agreement with Anthropic. The deal is expected to generate about $19 billion in contracted lease revenue over the … Read more